পদ্ধতির তুলনা করুন

	Gastroparesis Cardinal Symptom Index	ইরিটেবল বাওয়েল সিনড্রোমের জন্য রোম IV ডায়াগনস্টিক ক্রাইটেরিয়া	সংক্ষিপ্ত ইনফ্ল্যামেটরি বাওয়েল ডিজিজ প্রশ্নাবলী
ক্ষেত্র	পরিপাকতন্ত্র বিজ্ঞান	পরিপাকতন্ত্র বিজ্ঞান	পরিপাকতন্ত্র বিজ্ঞান
পরিবার	Process / pipeline	Process / pipeline	Process / pipeline
উদ্ভবের বছর	2003	2016	2004
প্রবর্তক	Revicki, D. A., Rentz, A. M., Dubois, D., et al.	Rome Foundation (multinational expert consensus)	Guyonnet, D., Chassany, O., Ducroc, R., et al.
ধরন	Self-report	Diagnostic Criteria	Self-report
মৌলিক উৎস	Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150.	Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation.	Guyonnet, D., Chassany, O., Ducroc, R., Picard, C., Mouret, M., D'Haens, G., & Svartz, H. (2004). Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in France: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 20(4), 459–465.
অপর নাম	GCSI	Rome IV IBS, Rome Criteria	IBDQ-32, Short IBDQ
সম্পর্কিত	4	4	4
সারসংক্ষেপ	The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response.	The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.	The Short Inflammatory Bowel Disease Questionnaire (IBDQ-32) is a validated patient-reported outcome measure designed to assess the impact of inflammatory bowel disease (IBD)—both ulcerative colitis and Crohn's disease—on health-related quality of life. Derived from the original 32-item IBDQ, this instrument comprises four domains: Bowel Symptoms, Systemic Symptoms, Social Function, and Emotional Function. The IBDQ-32 is responsive to treatment and is increasingly used in IBD clinical trials and practice.